MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients
The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13